Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (NYSE: RMD) drives innovation in digital health and respiratory care through cloud-connected medical devices and remote patient management platforms. This news hub provides investors and healthcare professionals with timely updates on the company's market activities and clinical advancements.
Access curated press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnership announcements. Our repository tracks developments across ResMed's core focus areas: sleep apnea solutions, COPD management technologies, and out-of-hospital care software platforms.
Stay informed about FDA clearances, clinical trial results, and global market expansions through verified sources. The page serves as a comprehensive resource for monitoring ResMed's progress in merging medical device engineering with data-driven healthcare solutions.
Bookmark this page for streamlined access to strategic updates impacting respiratory care innovation and digital health investment opportunities. Check regularly for new developments in ResMed's mission to transform chronic disease management worldwide.
ResMed (NYSE: RMD) reported strong Q3 fiscal 2025 results with revenue growing 8% to $1.3 billion and operating profit up 14% to $426.3 million. The company achieved a gross margin improvement of 140 basis points to 59.3% and generated operating cash flow of $579 million.
Key financial metrics include diluted earnings per share of $2.48 and non-GAAP diluted earnings per share of $2.37. Revenue growth was driven by increased demand for sleep devices and masks portfolio, with U.S., Canada, and Latin America growing 9%, while Europe, Asia, and other markets grew 8% on a constant currency basis.
During the quarter, ResMed paid $78 million in dividends and repurchased 314,000 shares for $75 million. The board declared a quarterly dividend of $0.53 per share, payable on June 12, 2025.
Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology, has appointed Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Reporting to CEO Mick Farrell, Schwartz brings over 20 decades of finance experience from health tech and financial services sectors.
Schwartz joins from Illumina, where she served as Head of Investor Relations, managing shareholder engagement, corporate strategy, and financial performance communications. Her previous roles include Head of IR and Treasurer at MSCI, managing over $2 billion in investments and $4 billion in debt, and various leadership positions at Moody's and Citigroup.
This appointment aligns with Resmed's 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential through better sleep and breathing health solutions.
Resmed (NYSE: RMD) has announced the nationwide U.S. availability of NightOwl™, an FDA-cleared home sleep apnea test. The device is a fingertip sensor designed to diagnose obstructive sleep apnea (OSA) from home, addressing a critical healthcare gap where 80% of OSA cases remain undiagnosed.
The disposable device can record up to 10 nights of sleep data per patient, utilizing peripheral arterial tonometry technology to measure blood flow changes, oxygen saturation, and pulse rate. Key features include auto-scored results, integration with Resmed's Somnoware, and pairing with the myAir™ app for user guidance.
NightOwl's clinical validation through a multicenter study demonstrated close agreement with expert-scored sleep lab testing PSG in measuring sleep apnea severity. The technology aims to simplify the diagnostic process for both healthcare providers and patients, supporting timely diagnosis and treatment of OSA, which affects nearly one billion people globally.
Resmed (NYSE: RMD, ASX: RMD) has announced it will release its third quarter fiscal 2025 financial and operational results on Wednesday, April 23, 2025, after the NYSE market close. The company will host a webcast to discuss the results at 1:30 p.m. PDT / 4:30 p.m. EDT on the same day.
The earnings webcast will be accessible through the investor relations section of Resmed's website. A replay will be available approximately two hours after the webcast, with a phone replay option available until May 7, 2025. Resmed, operating in 140 countries, specializes in AI-powered digital health solutions, cloud-connected devices, and intelligent software for home healthcare, focusing on sleep and breathing care.
Resmed (NYSE: RMD) announced groundbreaking research published in The Lancet Respiratory Medicine showing that CPAP therapy significantly reduces mortality risk in sleep apnea patients. The largest-ever meta-analysis, analyzing over 1 million patients across 30 studies, revealed that CPAP users have a 37% lower risk of all-cause mortality and a 55% lower risk of cardiovascular-related death compared to non-users.
The study demonstrates a dose-response relationship, indicating greater survival benefits with more consistent CPAP use. This research included data from 10 randomized controlled trials and 20 real-world evidence studies, with an average follow-up period of nearly five years.
The findings are particularly significant given that obstructive sleep apnea (OSA) affects over one billion people worldwide, with more than 80% of cases remaining undiagnosed and untreated. The study establishes CPAP therapy as a life-saving intervention that requires only air, without drugs or surgery.
Resmed (NYSE: RMD, ASX: RMD) announced a comprehensive brand evolution to unify its portfolio under a single identity, marking a significant shift in its 35-year history. The health technology company, focused on sleep, breathing, and home care, aims to consolidate its brands, products, and services over the next couple of years.
The rebranding includes a new visual identity, logo, and brand voice, positioning Resmed as an approachable health technology leader. This evolution coincides with three major initiatives: a U.S. consumer campaign to destigmatize CPAP therapy, a primary care physician education campaign for earlier sleep apnea diagnosis, and a sleep health awareness campaign in Asia Pacific and Europe.
According to Resmed's 2025 Global Sleep Survey, one-third of respondents report sleep difficulties, with 34% having trouble falling asleep and 29% staying asleep. The company estimates that over 2.3 billion people worldwide suffer from sleep apnea, insomnia, COPD, or other respiratory insufficiency.
ResMed's fifth annual Global Sleep Survey of 30,026 people across 13 markets reveals a concerning global sleep crisis. People are losing nearly three nights of restorative sleep weekly, with one-third of respondents reporting sleep difficulties three or more times per week.
Key findings show that 71% of employed respondents have called in sick due to poor sleep, with highest rates in India (94%). About 18% of couples opt for 'sleep divorce' due to snoring and restlessness. Women experience poorer sleep quality than men (3.83 vs 4.13 quality nights per week).
The survey identifies primary sleep disruptors as stress (57%), anxiety (46%), and financial pressures (31%). Despite 89% believing sleep improves their well-being, only 24% would take immediate action to address sleep issues. Notably, 22% globally choose to 'just live with' poor sleep, reaching 41% in Australia.
ResMed (NYSE: RMD) reported strong Q2 FY2025 financial results with significant growth across key metrics. Revenue increased 10% to $1.3 billion, while operating profit surged 52% to $417.2 million. The company achieved notable margin improvements, with gross margin expanding 300 basis points to 58.6%.
Key highlights include operating cash flow of $309 million and diluted earnings per share of $2.34. The company's growth was driven by increased demand for sleep health and breathing products, along with digital health solutions. During the quarter, ResMed paid $78 million in dividends and repurchased 307,000 shares for $75 million.
The board declared a quarterly cash dividend of $0.53 per share, payable on March 20, 2025, to shareholders of record as of February 13, 2025.
ResMed (NYSE: RMD, ASX: RMD) has announced plans to release its second quarter fiscal 2025 financial and operational results on Thursday, January 30, 2025, after the New York Stock Exchange market close. The company will follow the release with a management-hosted webcast to discuss the quarterly results.
ResMed (NYSE: RMD, ASX: RMD) has announced that Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.
The company will provide an audio-only webcast of the presentation, which can be accessed through the investor relations section of ResMed's website. A replay of the webcast will be available for 30 days following the live presentation.
